

Special Issue

Immunotherapy for Acute Lymphoblastic Leukemia: Novel Strategies and Clinical Perspectives

Message from the Guest Editors

Acute lymphoblastic leukemia (ALL) remains one of the most challenging hematologic malignancies to treat, particularly in the relapsed and refractory setting. Over the past decade, immunotherapy has revolutionized treatment paradigms, offering novel approaches that harness the patient's own immune system to eradicate leukemic cells. Breakthroughs such as bispecific T-cell engagers, chimeric antigen receptor (CAR) T-cell therapies, and antibody–drug conjugates have transformed outcomes, while ongoing research continues to refine strategies to improve efficacy, durability, and safety. This Special Issue, *Immunotherapy for Acute Lymphoblastic Leukemia: Novel Strategies and Clinical Perspectives*, aims to highlight advances in preclinical research, translational studies, and clinical applications that are shaping the future of ALL therapy. Contributions will cover innovative therapeutic modalities, mechanisms of resistance, real-world clinical experiences, and perspectives on integrating immunotherapy into standard treatment algorithms.

Guest Editors

Dr. Paola Minetto

IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Dr. Francesco Grimaldi

Department of Clinical Medicine and Surgery, Università Federico II di Napoli, Naples, Italy

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/254172

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)